Cas:27178-87-6 sodium,2,3-dimethylnaphthalene-1-sulfonate manufacturer & supplier

We serve Chemical Name:sodium,2,3-dimethylnaphthalene-1-sulfonate CAS:27178-87-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

sodium,2,3-dimethylnaphthalene-1-sulfonate

Chemical Name:sodium,2,3-dimethylnaphthalene-1-sulfonate
CAS.NO:27178-87-6
Synonyms:Naphthalenesulfonicacid,dimethyl-,sodium salt (7CI,9CI);Petro AG;Naphthalenesulfonicacid,dimethyl-,sodium salt (1:1);Petro AGS;SODIUM DIMETHYLNAPHTHALENESULFONATE;Petro 250
Molecular Formula:C12H11NaO3S
Molecular Weight:258.26900
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:65.58000
Exact Mass:258.03300
LogP:3.44150

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like Naphthalenesulfonicacid,dimethyl-,sodium salt (7CI,9CI) chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Petro 250 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Petro AG Use and application,Petro AG technical grade,usp/ep/jp grade.


Related News: The three products for which it received the PLI approvals are betamethasone with a production capacity of 12 MT at an investment of Rs 31.43 crore, dexamethasone of 10 MT with an investment of Rs. 26.19 crore and prednisolone of 15 MT at Rs 39. 29 crore. This takes the total investment to Rs 96.91 core. Metformin D6 hydrochloride manufacturers The company’s greenfield facility in Vasanthnarsapura Karnataka Industrial Area, Tumkur district, Karnataka, is under construction and is expected to be commissioned by April, 2022, well before the PLI scheme deadline of April 1, 2023. 3-(2-Bromo-1-oxopropyl)-spiro[2H-1,3-benzoxazine-2,1′-cyclohexan]-4(3H)-one suppliers The Institute for Clinical and Economic Review (ICER) on Friday released its report examining the cost-effectiveness of Soliris, also known as eculizumab, as well as up-and-comer efgartigimod for patients with the myasthenia gravis. sulcofuron-sodium vendor & factory.